Major advances in the treatment of hepatitis C
The provision of funded treatment for hepatitis C in primary health is a fundamental change in the treatment of hepatitis C.
Pātiki and Waharua Kōpito patterns
Pātiki and Waharua Kōpito patterns
Are you at risk?
Check whether you’re at risk of hepatitis C and choose where to get tested
Between February 2019 and June 2024, around 6,400 New Zealanders with hepatitis C have been treated with Maviret through the public health system.
Maviret is simple to administer, has fewer side effects than previous treatments, and can potentially cure 98 percent of people with chronic hepatitis C.
Refer to the Pharmac website for further details about the funded treatment options and for information for people with hepatitis C, for prescribers and for pharmacists:
- Maviret for treating hepatitis C (for all patients without cirrhosis with compensated cirrhosis)
- Harvoni for treating hepatitis C (for all patients with decompensated cirrhosis)